The announcement on May 1st, 2026, that Jakafi XR has been approved by the FDA for patients managing myelofibrosis offers a new dosing option . Prior to this announcement, Jakafi was widely used in treatment of this and other conditions,, but had to be prescribed off-label. Now that Jakafi XR is approved, healthcare providers can be more confident in recommending this therapy.
Jakafi XR (ruxolitinib) is an extended-release tablet designed to treat this specific type of bone marrow cancer. As a Janus kinase (JAK) inhibitor, it works by targeting proteins that control the production of blood cells and immune system responses. The introduction of a once-daily formula provides a bioequivalent alternative to the original twice-daily Jakafi, simplifying the treatment regimen for many individuals.
Understanding myelofibrosis
Myelofibrosis is a rare form of bone marrow cancer. It is characterized by the buildup of scar tissue, known as fibrosis, within the bone marrow. This scarring disrupts the body’s ability to produce healthy blood cells. While the specific cause is not yet known, scientists believe it stems from genetic mutations in blood-producing stem cells.
- Fatigue and weakness.
- Anemia, which is a low count of red blood cells.
- An enlarged spleen, leading to a feeling of fullness.
- Night sweats and fever.
- Bone and joint pain.
- Easy bruising or bleeding.
It is important to work with your physician to manage these symptoms and determine a comprehensive treatment plan. Your doctor can provide a full diagnosis and explain the options that are right for your specific situation.
How Jakafi XR works to treat myelofibrosis
Jakafi XR is part of a class of medications known as Janus kinase inhibitors, or JAKi. The Janus kinase family of proteins plays a central role in signaling pathways that regulate blood cell formation and the body’s immune system response. In myelofibrosis, these pathways can become overactive, leading to the disease’s symptoms and progression. By blocking these specific JAK proteins, Jakafi XR is approved because it helps to normalize the production of blood cells and calm the immune response. This action can reduce the size of the spleen, alleviate symptoms like fatigue and night sweats, and slow the overall progression of the disease. The recent approval of Jakafi XR provides a new tool for physicians managing this condition. All decisions regarding treatment should be made in consultation with a qualified physician who can monitor your progress.
The significance of the FDA approval of Jakafi XR
The key development with Jakafi XR is its formulation as a once-daily pill. The original Jakafi requires twice-daily dosing to maintain its therapeutic effect. The FDA has determined that the new extended-release version is bioequivalent to the original. This means that the once-daily Jakafi XR delivers the same amount of active ingredient to the body over a 24-hour period as the twice-daily tablets. For patients managing a chronic condition like myelofibrosis, treatment consistency is vital. A once-daily dosing schedule can make it easier to adhere to a long-term treatment plan. Sourcing this medication through a reliable international pharmacy like IsraelPharm ensures that patients have continuous access to their prescribed treatment without interruption, supporting this simplified daily routine.
Dosing and administration
Jakafi XR is an oral tablet taken once per day, with or without food. Jakafi XR is approved, with the specific dosage determined by a physician based on the patient’s platelet count and overall health profile. It is critical for patients to follow their healthcare provider’s instructions and not to alter the dose or stop taking the medication without medical guidance. Regular blood tests are necessary to monitor the effects of the treatment and make any adjustments to the dosage. This ensures the medication is working safely and effectively. This monitoring is a standard part of treatment and should be discussed with your doctor.
Potential side effects and safety considerations
Like all medications, Jakafi XR comes with potential side effects. The most common are related to its effects on blood cell production. These can include a low platelet count (thrombocytopenia), which can cause bruising or bleeding, and a low red blood cell count (anemia), which may lead to fatigue. There is also a risk of infections. Other possible side effects may include dizziness, headaches, and diarrhea. Patients should be aware of these risks and maintain open communication with their physician about any side effects they experience. Your doctor can help you manage these effects and ensure your treatment remains safe. Jakafi XR is a powerful medication that is not a cure for myelofibrosis but can be effective in managing the disease.
Comparing treatments for myelofibrosis
Jakafi XR is a leading option for myelofibrosis, but other treatments exist. The best course of action depends on a patient’s health, age, and disease severity. The following table provides context on how Jakafi XR compares to other therapeutic approaches.
| Treatment | How it works | Pros | Cons | Typical use |
|---|---|---|---|---|
| Jakafi XR (ruxolitinib) | A Janus kinase (JAK) inhibitor that reduces spleen size and symptoms by blocking overactive signaling pathways. | Effective symptom relief, slows disease progression, once-daily oral tablet. | Does not cure myelofibrosis; potential for side effects like anemia and low platelets. | For intermediate or high-risk myelofibrosis patients, often when transplantation is not an option. |
| Other JAK Inhibitors | Similar to Jakafi, these drugs block JAK proteins to control symptoms and cell production. | Provide an alternative if Jakafi is not tolerated or is ineffective. | Different side effect profiles; may be less studied than Jakafi. | Used in similar contexts to Jakafi, depending on patient factors and drug availability. |
| Tyrosine Kinase Inhibitors | Block different proteins (tyrosine kinases) that are involved in cell growth and division. | Offer another targeted therapy mechanism. | May be less effective for primary myelofibrosis symptoms compared to JAK inhibitors. | More common in other related cancers, but sometimes used in myelofibrosis clinical trials. |
| Stem Cell Transplantation | Replaces the patient’s diseased bone marrow with healthy donor stem cells. | The only potential cure for myelofibrosis. | Highly aggressive, high risk of serious complications and mortality; requires a matched donor. | Reserved for younger, otherwise healthy patients with advanced, high-risk disease. |
How to access Jakafi XR through IsraelPharm
Once you and your physician have decided on a treatment plan involving Jakafi XR, the next step is to secure a reliable and consistent supply. For a long-term therapy, this consistency is just as important as the medication itself. IsraelPharm provides a trustworthy solution for sourcing your prescription medications. Patients sourcing Jakafi XR through IsraelPharm benefit from several key advantages. IsraelPharm is a licensed international pharmacy that provides access to the exact branded medication prescribed by your doctor. This ensures you receive Jakafi XR, not a substitute. For a chronic condition requiring ongoing treatment, our service focuses on supply continuity, delivering medication directly to your home to avoid treatment gaps. A valid prescription from a licensed physician is required for all orders, maintaining the direct oversight of your doctor. In addition to reliability, the cost of Jakafi XR through IsraelPharm is significantly lower than US retail pricing. Patients can learn more about arranging their supply by visiting the IsraelPharm website.
Further reading
- Incyte Announcement: FDA Approval of Jakafi® (ruxolitinib) Extended-Release Tablets: Company announcement
- Learn more about Myelofibrosis from the Mayo Clinic: Mayo Clinic
- JAK Inhibitors 101: IsraelPharm blogs
Frequently asked questions about Jakafi XR
What is Jakafi XR and how does it work for myelofibrosis?
Jakafi XR is an extended-release prescription medication used to treat myelofibrosis. Its active ingredient, ruxolitinib, is a Janus kinase (JAK) inhibitor. It works by blocking specific proteins that are overactive in myelofibrosis. This helps to control the production of blood cells in the bone marrow and calm parts of the immune system. By doing so, Jakafi XR can successfully reduce spleen size and alleviate symptoms like fatigue, night sweats, and bone pain associated with the condition.
Is Jakafi XR a cure for myelofibrosis?
No, Jakafi XR is approved as a treatment, not a cure for myelofibrosis. It is a treatment designed to manage the disease and improve quality of life. The medication works to control symptoms and slow the progression of the underlying condition. The only potential cure for myelofibrosis is a stem cell transplant. This procedure is a very intensive and high-risk option that is not suitable for all patients. Jakafi XR offers a long-term management strategy for many individuals with myelofibrosis.
What is the main difference between Jakafi and Jakafi XR?
The main difference is the dosing schedule. The original Jakafi is an immediate-release tablet that must be taken twice a day. The new Jakafi XR is an extended-release tablet that is taken only once a day. Jakafi XR is designed to be bioequivalent, meaning it provides the same total medicinal effect over 24 hours as the twice-daily version. This simplifies the treatment routine for patients, potentially making it easier to adhere to the prescribed therapy over the long term.
What are the most common side effects of taking Jakafi XR?
The most common side effects of Jakafi XR are related to its impact on blood counts. These include a low number of platelets, known as thrombocytopenia, which can lead to easier bruising or bleeding. Another is a low number of red blood cells, called anemia, which can cause fatigue. Other side effects can include infections, dizziness, and headaches. Patients should report any side effects to their doctor, who will monitor them through regular blood tests to ensure safety.
How is the correct dosage of Jakafi XR determined?
The correct dosage of Jakafi XR is determined by a physician based on several factors. The primary factor is the patient’s blood platelet count, which is checked before starting treatment and monitored regularly. The doctor will prescribe a starting dose and may adjust it over time based on the patient’s response to the medication and any side effects that occur. It is crucial that patients follow their doctor’s instructions exactly and do not change their dose without medical consultation.
How can I obtain Jakafi XR through IsraelPharm?
Now that Jakafi XR is approved, a standard prescription from a licensed physician is all that we need – “off-label” is no longer an issue. IsraelPharm is a licensed international pharmacy that can fill this prescription for you. The process involves providing your prescription and completing the order on the IsraelPharm website. The medication is then shipped directly to your home. This service ensures you receive the authentic, branded Jakafi XR while benefiting from lower international pricing and the convenience of reliable, continuous supply for your ongoing treatment plan.
Glossary
- Anemia: A condition where the blood lacks enough healthy red blood cells to carry adequate oxygen to the body’s tissues.
- Bioequivalent: A term for two drugs that have the same active ingredient and produce the same therapeutic effect in the body.
- Bone marrow: The soft, spongy tissue inside bones where blood cells are produced, including red cells, white cells, and platelets.
- Corticosteroids: A class of drugs that lowers inflammation in the body and can be used to relieve symptoms like fatigue or pain.
- Janus kinase (JAK): A family of proteins that transmits signals within a cell and plays a key role in immunity and blood cell development.
- Myelofibrosis: A rare type of bone marrow cancer that disrupts the body’s normal production of blood cells, causing extensive scarring.
- Platelets: Small, colorless cell fragments in our blood that form clots to stop or prevent bleeding when blood vessels are damaged.
- Stem cell transplantation: A medical procedure that replaces a person’s diseased bone marrow with healthy blood-forming stem cells from a donor.
- Tyrosine kinase: An enzyme that acts as an “on” or “off” switch in many cellular functions, including cell growth and division.
